Abstract
BackgroundMany biosimilars of monoclonal antibodies (mAbs) are becoming increasingly available as anticancer therapies, such as the rituximab, bevaciz......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
